Comparative Effectiveness and Modality‐Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer
Cancer Medicine · 2026
DOI: 10.1002/cam4.71619 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, 2026. Verfasst von Yongfeng Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen Univ…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Neoadjuvant Therapy. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Natural Science Foundation of Guangdong Province.
Abstract (Originalsprache)
Background
Neoadjuvant therapies, including chemotherapy (NACT), chemoradiotherapy (NACRT), and chemoimmunotherapy (NACIT), are standard for locally advanced gastric cancer (LAGC). Pathological response is a key surrogate for treatment effectiveness, but its correlation with long‐term outcomes across modalities remains unclear.
Methods
This retrospective cohort study analyzed 256 LAGC patients receiving neoadjuvant therapy (NACT n = 162; NACRT n = 48; NACIT n = 46) from January 2017 to December 2022. Pathological responses, disease‐free survival (DFS), and overall survival (OS) were evaluated using Kaplan–Meier estimates and Cox models.
Results
Compared to NACT, NACIT was associated with significantly improved DFS (HR = 0.75, p = 0.035), though no OS difference was observed. Although NACRT enhanced pathological response rates, this was not accompanied by a survival benefit. Crucially, major pathological response (MPR) strongly correlated with improved survival in the NACT and NACIT groups, but no significant association was observed in the NACRT group.
Conclusion
NACIT is associated with improved DFS for patients with LAGC, whereas NACRT suggests a ‘pathology‐prognosis mismatch,’ where improved pathological response may not reliably predict a survival advantage. These findings challenge the uniform application of pathological response as a surrogate endpoint and highlight the critical need for modality‐specific interpretation when evaluating neoadjuvant therapy efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, People's Republic of China.
ORCID-Profile: Yongfeng Zhu, Yi Zeng, Jianrong Guo, Haibo Qiu
Förderung
- Beijing Xisike Clinical Oncology Research Foundation
- Natural Science Foundation of Guangdong Province
Zitieren
APA
Zhu, Y., Chen, Z., Jo, M., Feng, S., Zeng, Y., Chen, X., Guo, J., Ding, C., Jin, Y., & Qiu, H. (2026). Comparative Effectiveness and Modality‐Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer. Cancer Medicine. https://doi.org/10.1002/cam4.71619
Vancouver
Zhu Y, Chen Z, Jo M, Feng S, Zeng Y, Chen X, et al. Comparative Effectiveness and Modality‐Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer. Cancer Medicine. 2026. doi:10.1002/cam4.71619
BibTeX
@article{Zhu2026,
author = {Zhu, Yongfeng and Chen, Zhenchong and Jo, Minju and Feng, Shoucheng and Zeng, Yi and Chen, Xiaojiang and Guo, Jianrong and Ding, Chao and Jin, Yukai and Qiu, Haibo},
title = {Comparative Effectiveness and Modality‐Dependent Prognostic Value of Pathological Response Following Neoadjuvant Therapy for Locally Advanced Gastric Cancer},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.71619}
}
EUVIMED